Sutro Biopharma (STRO) Non Operating Income (2024 - 2025)
Sutro Biopharma (STRO) reported Non Operating Income of -$8.8 million for Q4 2025, down 82.09% on a YoY basis from -$49.1 million in Q4 2024, and down 4.73% sequentially from -$8.4 million in Q3 2025.
Sutro Biopharma (STRO) Non Operating Income (2024 - 2025) Analysis & Trends
Sutro Biopharma (STRO) has 2 years of Non Operating Income data on file, last reported at -$8.8 million in Q4 2025.
- For the quarter ending Q4 2025, Non Operating Income fell 82.09% year-over-year to -$8.8 million; the trailing twelve-month figure through Dec 2025 stood at -$32.8 million (down 345.74% YoY), and the FY2025 full-year result was -$32.8 million, down 345.69% from the prior year.
- Non Operating Income eased to -$8.8 million in Q4 2025, from -$8.4 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $19.1 million in Q3 2024 to a low of -$8.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -8.59 Mn |
| 10 | Sutro Biopharma | 192.86 Mn | 51.43 Mn | - | -8.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -8.80 Mn |
| Sep 30, 2025 | -8.40 Mn |
| Jun 30, 2025 | -8.17 Mn |
| Mar 31, 2025 | -7.45 Mn |
| Dec 31, 2024 | -4.83 Mn |
| Sep 30, 2024 | 19.13 Mn |
| Jun 30, 2024 | 675,000.00 |
| Mar 31, 2024 | -1.62 Mn |